Stock Watch: The Pandemic’s Effects On Big Pharma – A Year In
Negative Effects On Revenue Were Partly Balanced In Other Areas
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.
You may also be interested in...
If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.
Novartis and Takeda’s R&D efforts saw an impact from the COVID-19 pandemic, but both Lutz Hegemann and Andrew Plump believe that when the next pandemic hits, the industry and regulators will be better prepared for it.
Novartis’s comparatively anemic revenue growth and Lilly’s sales shortfall suggest that hopes for an immediate sector recovery from the pandemic are premature.